Comparative Pharmacology
Head-to-head clinical analysis: ANUSOL HC versus TOPICORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANUSOL HC versus TOPICORT.
ANUSOL HC vs TOPICORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone, a corticosteroid, binds to glucocorticoid receptors, inhibiting phospholipase A2 activity and reducing prostaglandin and leukotriene synthesis. It also suppresses cytokine production and inflammatory cell migration, leading to decreased edema, erythema, and pruritus in anorectal tissues.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing production of prostaglandins and leukotrienes, leading to anti-inflammatory, antipruritic, and vasoconstrictive effects.
Apply a thin layer to the affected area rectally 2 to 4 times daily, or after each bowel movement, for up to 7 days. Each application should not exceed 1 gram.
Apply a thin film to the affected skin areas twice daily. Maximum adult dose: 50 g/week. Not for use on the face, axillae, or groin. Do not use under occlusive dressings.
None Documented
None Documented
Terminal elimination half-life of hydrocortisone is approximately 1.5-2 hours (range 1-3 h) in adults; clinical effect outlasts half-life due to intracellular receptor-mediated action.
Terminal elimination half-life: 2-4 hours for parent drug; clinical effect lasts longer due to receptor binding
Renal (primarily as metabolites) >80%; fecal ~15%; <2% unchanged in urine due to extensive hepatic metabolism. Biliary excretion is negligible.
Renal (metabolites): ~75%; Fecal: ~25%
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid